Applied Genetic Technologies Corporation announced it had exceeded the enrollment target in the Company's SKYLINE trial of AGTC-501, a recombinant AAV vector-based gene therapy developed for the treatment of X-linked retinitis pigmentosa (XLRP). A total of 14 patients have been enrolled across the high and low dose groups, exceeding the planned target enrollment of 12. SKYLINE is a multi-site expansion of the ongoing Phase 1/2 study in which patients are randomized to either a high or low dose of AGTC-501 with the primary objective to identify the proportion of treated eyes that demonstrate improvement from baseline in measures of visual sensitivity and visual acuity as well as the patient's ability to navigate a mobility maze more successfully under varying light and challenge conditions.

Importantly, this is the first trial that has the potential to demonstrate a correlation of visual sensitivity and visual acuity with the maze outcome, a key functional endpoint in the VISTA trial. The Company anticipates releasing the following, subject to any continuing impact of COVID-19: 24-month results from the ongoing Phase 1/2 clinical trial of AGTC-501 in the third quarter of calendar year 2022; 12-month results from the SKYLINE trial in the first quarter of calendar year 2023; and interim results from the VISTA trial in the first half of calendar year 2023.